DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Vir Biotechnology's - 1 sotrovimab - 1 Cowen - 1 Phil Nadeau - 1 Nadeau - 1 Leroy Leo - 1 Shailesh - 1
Top related locs:
Bengaluru
Top related orgs:
GSK plc - 1 COVID - 1 Alnylam Pharmaceuticals - 1 Vertex Pharmaceuticals - 1 Thomson - 1

Search resuls for: "Phil Nadeau"


3 mentions found


☆ Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial
  + stars: | 2023-07-20 | by ( ) www.reuters.com   time to read: +1 min
July 20 (Reuters) - Vir Biotechnology's (VIR.O) shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage trial. The biotechnology firm, which came into prominence through its COVID-19 antibody therapy sotrovimab developed in partnership with GSK plc (GSK.L), lost over $1 billion in market capitalization in early trade hit by the therapy's failure. The company said it will conduct further analyses on the trial data to "better understand these outcomes", but TD Cowen analyst Phil Nadeau does not expect the therapy to undergo further development. The company is developing antibody therapies against hepatitis B and D, for which data is expected later this year, and also has development programs for COVID-19, HIV and influenza. Reporting by Leroy Leo in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.
Persons: Vir Biotechnology's, sotrovimab, Cowen, Phil Nadeau, Nadeau, Leroy Leo, Shailesh Organizations: GSK plc, COVID, Alnylam Pharmaceuticals, Vertex Pharmaceuticals, Thomson Locations: Bengaluru
☆ Biogen and Eisai's latest clinical trial just crossed the finish line. Here's why analysts say the results could disrupt the future of Alzheimer's care.
  + stars: | 2022-09-28 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +7 min
It's a complicated, debilitating illness and drug companies have struggled for years to come up with viable treatments. On Tuesday September 27, Biogen and Eisai announced that lecanemab slowed the rate of cognitive decline in Alzheimer's patients by 27%. Analysts say that this positive result could lead to it becoming a blockbuster drug for the companies. Other big drug companies such as Roche Holdings and Eli Lilly are pursuing similar treatments, with results expected to come later this year and early next year, respectively. "I think people's confidence in the amyloid hypothesis would go down even further, but ultimately people would wait to see what those other data events show," he said.
☆ Biogen's latest clinical trial is inching towards the finish line. Here's why analysts say the results could disrupt the future of Alzheimer's care.
  + stars: | 2022-09-19 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +7 min
It's a complicated, debilitating illness and drug companies have struggled for years to come up with viable treatments. Other big drug companies such as Roche Holdings and Eli Lilly are pursuing similar treatments, with results expected to come later this year and early next year, respectively. "I think people's confidence in the amyloid hypothesis would go down even further, but ultimately people would wait to see what those other data events show," he said. Negative results might give a boost to companies that are exploring alternate ways to treat Alzheimer's disease. And though Biogen's drug is furthest along in development, it's far from being the only treatment being tested for Alzheimer's.
0 next >>
Total: 3